Infigratinib - Helsinn/QED Therapeutics
Alternative Names: BBP-831; BGJ-398; BGJ-398 phosphate; Febseltiq; Infigratinib phosphate; NVP-BGJ398; TRUSELTIQLatest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Novartis
- Developer Array BioPharma; Helsinn; LianBio; Novartis; Novartis Oncology; QED Therapeutics
- Class Aniline compounds; Antineoplastics; Chlorobenzenes; Methylurea compounds; Phenyl ethers; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cholangiocarcinoma
- Phase III Achondroplasia; Bladder cancer; Urogenital cancer
- Phase II/III Hypochondroplasia
- Phase II Adenocarcinoma; Gastric cancer; Head and neck cancer; Oesophageal cancer
- Phase I/II Solid tumours
- No development reported Breast cancer; Glioma
- Discontinued Glioblastoma; Haematological malignancies; Malignant melanoma
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Bladder-cancer(Neoadjuvant therapy) in USA (PO, Capsule)
- 24 Jan 2025 Phase-II/III clinical trials in Hypochondroplasia (In children, In adolescents) in USA, United Kingdom, Sweden, Spain, Singapore, Portugal, Norway, France, Canada, Australia (PO) before January 2025 (BridgeBio Pharma pipeline, January 2025) (NCT06410976)
- 01 Jan 2025 National Cancer Institute terminates a phase I/II trial in Urogenital cancer in USA (PO) as drug manufacturer made the business decision to cease all infigratinib oncology research in the US and withdrew the IND (NCT04228042)